Latest Tempus News & Updates

See the latest news and media coverage for Tempus. We track all announcements, press releases, and industry mentions in real time, all in one place.

Tempus

AI-enabled precision medicine platform

tempus.com

Headquarters: Chicago, United States
Founded year: 2015
Company type: Public company
Number of employees: 3,000–5,000
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about Tempus

In short: Tempus announced a $1.5 billion deal to acquire Personalis, reported a 22% rise in Q2 revenue, and received several key FDA clearances.

Company announcements

September 11 Tempus

Tempus builds largest multimodal whole-genome dataset for AI healthcare

The company releases 100,000 disease-specific genomes with clinical outcomes via its Early Adopter Program, targeting general availability in mid-2027.

September 9 Tempus

Tempus secures $9.5M for autonomous AI cardiology

ARPA-H funds the ADVOCATE program to build an autonomous clinical agent providing heart failure care.

August 6 Tempus

Tempus CEO discusses stock undervaluation in shareholder letter

He argues the stock trades at a discount to both diagnostic and AI peers, plans to execute and improve investor communication.

July 30 Tempus

Tempus reports second quarter 2026 results

Total revenue grew 22% year-over-year to $382.5 million, and the company announced an agreement to acquire Personalis.

Media coverage

Today Blockonomi

Tempus AI (TEM) Stock Surges 11% on Piper Sandler Upgrade and Federal Grant News

Tempus AI (TEM) stock jumped 11% after Piper Sandler's upgrade to Overweight, a Q2 earnings beat, and a $9.5M federal grant for cardiology AI development.

Yesterday 24/7 Wall St.

Tempus AI leads the session with a 10.5% gain as losers bite harder

Tempus AI closed the session up 10.5%, the only double-digit move among 111 tracked names. The...

September 9 Yahoo

ARPA-H to award $62.7M for AI in cardiovascular care

Companies including Tempus AI and Updoc are tasked with building an agentic AI system for managing heart failure.

September 5 BigGo Finance

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation

Moderna and Merck's personalized mRNA cancer vaccine mRNA-4157 achieved a breakthrough in Phase 3 trials, triggering a sharp rally in ...

Never miss news about Tempus

Track Tempus and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Tempus competitors & trending companies

Browse news for competitors to Tempus and other trending companies.